A Markov Model of Treatment of Newly Diagnosed Epilepsy in the UK: An Initial Assessment of Cost-Effectiveness of Topiramate

• Published in: The European journal of health economics Vol. 4; no. 4; pp. 271 - 278
• Main Authors: Remák, E., Hutton, J., Price, M., Peeters, K., Adriaenssen, I.
• Format: Journal Article
• Language: English
• Published: Germany Springer-Verlag 01.11.2003; Springer Nature B.V
• Subjects: Anticonvulsants; Convulsions & seizures; Drug therapy; Economic costs; Economic models; Epilepsy; Exanthema; Health economics; Markov chains; Markov models; Mortality; Original Papers; Seizures; Side effects; Utilities costs
• ISSN: 1618-7598; 1618-7601
• DOI: 10.1007/s10198-003-0176-3

Long-term comparative trials among newer antiepileptic drugs are lacking; therefore decision models are needed to guide treatment decisions. The goal of this study was to develop an economic model of newly diagnosed epilepsy in the UK and to provide the first assessment of topiramate. A Markov model was developed combining data from clinical trials, cost-of illness, mortality, and utility studies. Expected costs and utilities associated with treatment strategies (first- and second-line treatments) were compared to find the cost-effectiveness frontier. First- and second-line monotherapy with topiramate or carbamazepine in partial seizures was less costly and more effective than other scenarios. In generalised seizures first-line topiramate was cost-effective with valproate or lamotrigine as second-line treatments depending on the set of utilities used. Models provide a relevant framework within which costs and health gains of antiepileptic drugs treatment options can be studied. Our findings are further evidence of the promising role of topiramate for patients with newly diagnosed epilepsy.